Hepatocellular carcinoma systemic therapy options mature
Atezolizumab plus bevacizumab maturity, durvalumab plus tremelimumab adoption, and TIGIT-class programs are restructuring advanced HCC.
Hepatocellular carcinoma was a sorafenib-only category for nearly a decade. Atezolizumab plus bevacizumab established IO plus VEGF as first-line in 2020; durvalumab plus tremelimumab added a dual-IO option, and TIGIT-class programs are reading out in late-stage trials. The diagnostic-pathway question (HCC is often diagnosed late because surveillance in cirrhosis is uneven) is the addressable-population enabler.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is glioblastoma?
- SnapshotAdult diffuse glioma therapy reference (2026)